Rivastigmine Patch, Extended Release
Product Images NDC 70771-1949

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 70771-1949). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4.6 mg/24 Hrs (Eb52b342 1672 42e7 Bb4c 9c8f1bce7fc3 01)

This text appears to be a label or information sheet about Rivastigmine Transdermal System, containing a dosage of 4.5 mg/24 hours. It is intended for transdermal use only and contains 3 systems per package.*

FDA Label Image

9.5 mg/24 Hrs (Eb52b342 1672 42e7 Bb4c 9c8f1bce7fc3 02)

FDA Label Image

13.3 mg/24 Hrs (Eb52b342 1672 42e7 Bb4c 9c8f1bce7fc3 03)

This text appears to be a description of a medication administration system. It seems to refer to Rivastigmine Transdermal System, specifying its components, usage instructions, and quantity of systems included. The system seems intended for transdermal use only. The text also mentions the NDC number for identification purposes. There are details about the delivery of the system and its components, including the necessary procedures for application. It emphasizes the importance of proper storage and usage.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.